Oppenheimer initiates coverage on Conatus Pharmaceuticals (NASDAQ: CNAT) with a Outperform rating and a price target of $16.00.Analyst Jay Olson ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot New Coverage New Coverage